Portfolio Rapha Capital Management

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel

By Kevin SlawinDecember 2, 2018February 4th, 2021No Comments

Bellicum Pharmaceuticals, Inc.
Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
Results show high rates of Relapse Free Survival and Overall Survival in pediatric patients with acute leukemias with median follow-up of 17 months
December 2, 2018

Previous PostPoseida Therapeutics: Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
Next PostBellicum Pharmaceuticals, Inc.: Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions